Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment
Vaidya JS., Bulsara M., Baum M., Tobias JS., Wenz F., Massarut S., Pigorsch S., Alvarado M., Douek M., Saunders C., Flyger HL., Eiermann W., Brew-Graves C., Williams NR., Potyka I., Roberts N., Bernstein M., Brown D., Sperk E., Laws S., Sütterlin M., Corica T., Lundgren S., Holmes D., Vinante L., Bozza F., Pazos M., Le Blanc-Onfroy M., Gruber G., Polkowski W., Dedes KJ., Niewald M., Blohmer J., McCready D., Hoefer R., Kelemen P., Petralia G., Falzon M., Joseph DJ.
© 2021, The Author(s). In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.